

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Qiming U.S. Healthcare Fund II, L.P.</u> (Last) (First) (Middle) 11100 NE 8TH ST. SUITE 200 (Street) BELLEVUE WA 98004 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Icosavax, Inc. [ICVX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) _____ Former 10% Owner
	3. Date of Earliest Transaction (Month/Day/Year) 08/02/2021	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/02/2021		C		3,310,228	A	\$0.00 ⁽¹⁾	3,310,228	D ⁽²⁾	
Common Stock	08/02/2021		P ⁽⁵⁾		200,000	A	\$15	3,510,228	D ⁽²⁾	
Common Stock	08/02/2021		P		8,018	A	\$15	3,518,246	D ⁽³⁾	
Common Stock	08/02/2021		P		13,333	A	\$15	3,523,561	D ⁽⁴⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A-1 Preferred Stock	\$0.00	08/02/2021		C		12,480,498		(1)	(1)	Common Stock	3,003,224	(1)	0	D ⁽²⁾	
Series B-1 Preferred Stock	\$0.00	08/02/2021		C		1,275,817		(1)	(1)	Common Stock	307,004	(1)	0	D ⁽²⁾	

1. Name and Address of Reporting Person*
Qiming U.S. Healthcare Fund II, L.P.
 (Last) (First) (Middle)
 11100 NE 8TH ST. SUITE 200
 (Street)
 BELLEVUE WA 98004
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Qiming U.S. Healthcare GP II, LLC
 (Last) (First) (Middle)
 11100 NE 8TH ST SUITE 200
 (Street)
 BELLEVUE WA 98004
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
MCDADE MARK
 (Last) (First) (Middle)
 11100 NE 8TH ST SUITE 200

(Street)		
BELLEVUE	WA	98004
(City)	(State)	(Zip)

Explanation of Responses:

1. On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's common stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, Qiming U.S. Healthcare Fund II, L.P. ("Qiming") is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer.
2. The securities are directly held by Qiming. Qiming U.S. Healthcare GP II, LLC ("Qiming GP") is the General Partner of Qiming. Gary Rieschel and Mark McDade are the managing members of Qiming GP. As a result, each of Qiming GP and Messrs. Rieschel and McDade may be deemed to beneficially own the shares held by Qiming.
3. Shares reported herein as purchased on August 2, 2021 represent 8,018 shares of Common Stock purchased by Mark McDade.
4. Shares reported herein as purchased on August 2, 2021 represent 13,333 shares of Common Stock purchased by Gary Rieschel.
5. Shares reported herein as purchased on August 2, 2021 represent 200,000 shares of Common Stock purchased by Qiming.

Remarks:

<u>/s/ Qiming U.S. Healthcare Fund II, L.P., by Qiming U.S. Healthcare GP II, LLC, its General Partner</u>	<u>08/02/2021</u>
<u>/s/ Mark McDade</u>	<u>08/02/2021</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.